---
figid: PMC2409614__90-6601627f3
figlink: /pmc/articles/PMC2409614/figure/fig3/
number: F3
caption: The development of tamoxifen (TAM)-resistant breast cancer and the changing
  role of oestradiol (E2) in the life and death of ER-positive cancer cells. (A) E2-stimulated
  growth is inhibited by the use of an aromatase inhibitor to block oestrogen synthesis
  or TAM to block the ER and prevent oestrogen-stimulated gene transcription. Optimal
  antioestrogenic effects occur in the absence of pre-existing cell surface signalling
  mechanisms. (B) Prolonged use of TAM promotes an increase in HER2/neu cell surface
  signalling that creates a survival pathway phosphorylating the TAM ER complex and
  coactivator proteins. The transcription complex becomes activated to enhance gene
  activation and TAM-stimulated growth. If this is Phase I resistance, then oestrogen
  will also promote growth; so an aromatase inhibitor is an appropriate second-line
  therapy. If it is Phase II resistance, E2 causes apoptosis. (C) In Phase II tamoxifen
  resistance, the E2 ER complex collapses the survival mechanisms by dramatically
  reducing the level of cell surface signalling by preventing HER2/neu mRNA transcription
  and the nuclear level of NFκB, a transcription factor. (D) In Phase II tamoxifen
  resistance, the E2 ER complex also enhances the synthesis of Fas receptor mRNA and
  protein which, in the presence of Fas ligand (FasL) activates caspase 8 and a cascade
  of events resulting in apoptosis. These figures are summaries of the mechanisms
  described in  and .
pmcid: PMC2409614
papertitle: Targeting oestrogen to kill the cancer but not the patient.
reftext: J S Lewis, et al. Br J Cancer. 2004 Mar 8;90(5):944-949.
pmc_ranked_result_index: '23514'
pathway_score: 0.9688079
filename: 90-6601627f3.jpg
figtitle: Development of tamoxifen (TAM)-resistant breast cancer and the changing
  role of oestradiol (E2) in the life and death of ER-positive cancer cells
year: '2004'
organisms: Homo sapiens
ndex: 7fb4b796-deb8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2409614__90-6601627f3.html
  '@type': Dataset
  description: The development of tamoxifen (TAM)-resistant breast cancer and the
    changing role of oestradiol (E2) in the life and death of ER-positive cancer cells.
    (A) E2-stimulated growth is inhibited by the use of an aromatase inhibitor to
    block oestrogen synthesis or TAM to block the ER and prevent oestrogen-stimulated
    gene transcription. Optimal antioestrogenic effects occur in the absence of pre-existing
    cell surface signalling mechanisms. (B) Prolonged use of TAM promotes an increase
    in HER2/neu cell surface signalling that creates a survival pathway phosphorylating
    the TAM ER complex and coactivator proteins. The transcription complex becomes
    activated to enhance gene activation and TAM-stimulated growth. If this is Phase
    I resistance, then oestrogen will also promote growth; so an aromatase inhibitor
    is an appropriate second-line therapy. If it is Phase II resistance, E2 causes
    apoptosis. (C) In Phase II tamoxifen resistance, the E2 ER complex collapses the
    survival mechanisms by dramatically reducing the level of cell surface signalling
    by preventing HER2/neu mRNA transcription and the nuclear level of NFκB, a transcription
    factor. (D) In Phase II tamoxifen resistance, the E2 ER complex also enhances
    the synthesis of Fas receptor mRNA and protein which, in the presence of Fas ligand
    (FasL) activates caspase 8 and a cascade of events resulting in apoptosis. These
    figures are summaries of the mechanisms described in  and .
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CASP5
  - CYP19A1
  - CASP8
  - CASP6
  - MAP6
  - CASP7
  - CASP1
  - FAS
  - REL
  - RELA
  - CASP4
  - ERBB2
  - OPN3
  - CASP12
  - RELB
  - EGFR
  - CASP2
  - CASP14
  - NFKB2
  - CASP10
  - FADD
  - NFKB1
  - CASP3
  - CASP9
  - FASLG
  - Tamoxifen
genes:
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP5
  entrez: '838'
- word: Aromatase
  symbol: aromatase
  source: hgnc_alias_symbol
  hgnc_symbol: CYP19A1
  entrez: '1588'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP8
  entrez: '841'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP6
  entrez: '839'
- word: stops
  symbol: STOP
  source: hgnc_alias_symbol
  hgnc_symbol: MAP6
  entrez: '4135'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP7
  entrez: '840'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP1
  entrez: '834'
- word: Fas
  symbol: FAS
  source: hgnc_symbol
  hgnc_symbol: FAS
  entrez: '355'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP4
  entrez: '837'
- word: HER2/neu
  symbol: NEU
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: ERO
  symbol: ERO
  source: hgnc_alias_symbol
  hgnc_symbol: OPN3
  entrez: '23596'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP12
  entrez: '100506742'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: HER2/neu
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP2
  entrez: '835'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP14
  entrez: '23581'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP10
  entrez: '843'
- word: FADD
  symbol: FADD
  source: hgnc_symbol
  hgnc_symbol: FADD
  entrez: '8772'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP3
  entrez: '836'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP9
  entrez: '842'
- word: FasL
  symbol: FasL
  source: hgnc_alias_symbol
  hgnc_symbol: FASLG
  entrez: '356'
chemicals:
- word: Tamoxifen
  source: MESH
  identifier: D013629
diseases: []
figid_alias: PMC2409614__F3
redirect_from: /figures/PMC2409614__F3
figtype: Figure
---
